Archive for Stock Market News – Page 43

Expert Says, ‘Shell Should Have a Higher Valuation’

Source: Ron Struthers  (10/20/22) 

More and more North American natural gas will end up as LNG to Europe in the coming years. Soon we will compete on price. Expert Ron Struthers believes Royal Dutch Shell Plc. offers a compelling valuation compared to its peers and will benefit from this market transition.

Do as I do, not what I say! We had a prime example of this on Wednesday from President Biden, as he told oil and gas companies that they should not buy back shares or pay dividends but instead spend the money on exploration.

But what did he do?

U.S. Oil and Gas

He canceled the Keystone XL Pipeline on his first day of office, and then he halted all leasing and permits for oil and gas exploration on federal lands. In May of this year, he canceled three offshore oil and gas leases, and as of now, they have not leased one acre of land to drill.

J.t this past July, Biden proposed a policy to end all tax incentives to oil and gas companies. Would you think this gives no confidence for oil and gas companies to explore?

Of course, they have curtailed exploration, and most are focused on shareholder returns, and oil and gas production has declined, and all the inventories of oil, gas, gasoline, diesel and heating fuel, etc., are at multi-year lows.

Electricity prices along the Atlantic coast of the United States are set to increase 50-60% year-on-year as gas supplies become squeezed to meet winter heating and generation needs. New England on-peak power prices have averaged slightly below US$80/MWh in September, forward electricity prices for December 2022 have been trending well above US$200/MWh recently.

The operator of New England’s power grid has already warned of potential blackouts in the winter in case of a severe cold spell. Before Biden took office, the U.S. was producing more oil than it was using and more than the Russians or the Middle East. oil and gas companies are the favorite whipping boys of politicians anytime prices rise.

Meanwhile, today we hear the Biden administration is granting US$2.8 billion to companies to expand electric-vehicle battery production. This will do nothing to ease the current energy crisis.

Gas Shortage

Last week we saw the first decent increase in gas storage that lifted the level off the bottom of the five-year average.

This will not help curtail high prices this winter, as the next two charts show rising demand.

You can see from these charts that gas for electrical production is above the five-year average, and exports of LNG are at record levels, taking advantage of the higher European prices.

More and more gas will be diverted to higher prices leading to higher prices and possible shortages in North America. Getting data in Canada is very hard, and what is there is out of date. Ontario provides quarterly reports, but these have not even published the Q4 2021 report yet.

The U.S. has now become the largest exporter of LNG and is now importing about 15% of gas production as LNG, mostly to Europe. What is important is that approved LNG projects will ramp this up to over 50% of U.S. production.

I do know Ontario is scrambling for more natural gas for electrical generation.

Alberta recently had pipeline problems that should have increased storage. The only decent report is from Stats Canada, but they are months behind.

They have just reported July storage numbers, and it is not looking good — well below 2020 and 2021 levels.

• July 2022 15,840,398 cubic meters (15,840,398cm)
• July 2021 18,610,093cm
• July 2020 21,075,478cm
• July 2019 17,514,295cm

We have the most incompetent leadership in Canada, the U.S., and Europe like never before. Turfing the PMs in the UK is becoming a habit, as Truss resigned today. You can count on governments to make this energy crisis far worse.

You often see in the news about Canada’s potential or capacity to export LNG. This is just nonsense or fake news; Canada has zero export capacity for LNG.

The first to come on line will be TC Energy Corp.’s  (TRP:NYSE) pipeline, as shown in my report on them, and that will not be until 2025.

Royal Dutch Shell Plc. (SHEL:NYSE) leads a consortium actually building the LNG plant processing TC Energy gas.

Statista has provided some excellent graphics that will help you understand the dire straits that Europe is in this winter.

Almost all these countries are dependent on fossil fuels.

The Nord Stream

The Nord Stream 2 was completed since this 2021 graphic but does not matter anyway, as it was blown up along with Nord Stream 1. What is coming from Ukraine is questionable, as the Russian invasion has started to target energy infrastructure.

I expect this is part of a plan before a Russian offensive this winter. There is no solution for this winter; Europe won’t have enough energy. Germany will probably have to shut down industry and plunge into a deep recession and deep freeze, along with some other European countries.

The U.S. has now become the largest exporter of LNG and is now importing about 15% of gas production as LNG, mostly to Europe. What is important is that approved LNG projects will ramp this up to over 50% of U.S. production.

The gas will go to the highest bidder, so as time passes, the U.S. and Canada will compete with Europe for natural gas. Nobody knows how long this war will last and what damage to energy infrastructure will result.

Remember that most troops killed in war are either transporting energy or guarding it. This war will be no different other than there being a lot more gas and nuclear energy facilities compared to past wars.

And most likely, politicians will screw things up with their plans for the transition to green energy. In another desperate move ahead of the U.S. mid-term elections, Biden is releasing another 15 million barrels from the SPR.

This will be the last because, after the mid-term elections, there will be a gridlocked government. The Republicans will win the House and maybe the Senate too, but even if they win both, Biden can veto any legislation, and it goes back to the House and Senate but must get a 2/3 majority vote.

That will not happen. However, markets love a government that can do nothing, and this may be a reason that extends this bear rally if and when one starts.

I believe it is a perfect time with the politically driven correction in oil and gas and the producers to buy one of the blue-chip integrated oil companies that will benefit from tighter energy markets and more LNG exports. Royal Dutch Shell Plc. (SHEL:NYSE) has been in my Millennium Index before.

We sold it in 2014 for an 81% profit plus dividends because I believed oil was heading down significantly, and indeed it dropped from the $100 area to $50 and lower.

Now is a good time to add Shell to the Millennium Index.

Shell Plc.

Royal Dutch Shell Plc. (SHEL:NYSE) is probably the best-known brand in the world, serving 32 million customers per day and 84 million loyal members. They have about 46,000 locations (more than Mcdonald’s) in 80 markets.

Their goal by 2025 is to have 40 million customers and 55,000 locations. They currently have over 105,000 EV charge points and plan to grow this to over 500,000 in 2025. I expect the Shell brand will remain at the top for a long time.

Shell pays dividends in U.S. dollars, and the last quarterly dividend was US$0.25 per share, and since each ADR represents two ordinary shares, the quarterly dividend on the ADR was US$0.50. Based on a US$2.00 dividend per year and the current ADR share price, that is a yield of 3.8%.

I like Shell at this time because of its superior and well-known brand, and at current prices, the stock is valued better than its peers like Exxon, Chevron, and BP, for example.

Before Covid-19 hit, they were paying a US$0.47 dividend, and it dropped to the US$0.17 level in 2020 and early 2021.

I expect Shell will get back to the US$0.47 level in the next couple of years. Shell has a growing portfolio in LNG as well as renewable projects coming on stream from now to 2024.

Production in the North Sea

They are bringing their Jackdaw Field into production in the North Sea, which can produce more than 6% of the UK’s gas production in the coming years. Shell is also going ahead with the Crux Field in Australia, which will provide gas for their floating LNG facility.

Pursuing LNG Canada, Shell has a 40% leading interest in building out the facility in Kitimat, B.C. Kitimat was chosen as the ideal location for the facility due to the easy access to abundant, low-cost natural gas from Alberta/British Columbia’s vast resources.

The location also benefits from a relatively short shipping distance to north Asia, one of the fastest-growing gas markets in the world. The shipping route is approximately 50% shorter than from the US Gulf of Mexico and avoids the Panama Canal. =

The project has strong support from the local community, including indigenous First Nations, as well as from the local government. TC Energy will supply the gas.

Recent performance has been strong, as shown below, and Shell is delivering stronger cash flow from operations than its peers. Shell should have a higher valuation, not a lower one.

A large part of Shell’s LNG is a traded portfolio using other’s assets. Their renewable segment is doing well, with the input cost to electrical price spread quite large at this time. This looks to continue for some time, and we will probably see the spread widen with even higher electricity prices.

Shell’s chemical division is significant, contributing almost 20% of the earnings in Q2. Chemicals are cyclical. and their division has seen a weaker performance. Shell says now at a bottom of the cycle based on the chemicals they are in.

More important is that their Pennsylvania plant starts production of polyethylene this year, which is currently a high-margin plastic product, so this will greatly improve their Chemical Division.

Shell’s oil and gas production has declined some in the last several years, but the quality of their portfolio of assets has improved considerably, and they are now a lot more profitable on a little less production.

Comparing Q2 2022 to Q2 2013 in it’s presentation, when oil prices were about the same, Shell produced +65% adjusted earnings in Q2 2022 compared to Q2 2013 and three times the cash flow and doubled shareholder distributions.

Recent performance has been strong, as shown below, and Shell is delivering stronger cash flow from operations than its peers. Shell should have a higher valuation, not a lower one.

Shell has a US$6 billion share buyback underway in Q3, something similar will continue in Q4.

Basically, Shell looks at the share valuation to determine the mix of dividends and stock buyback. The US$7.2 billion payout in Q2 to investors was a record. The dividend is very stable, and buybacks will help increase the dividend.

Conclusion

I like Shell at this time because of its superior and well-known brand, and at current prices, the stock is valued better than its peers like Exxon, Chevron, and BP, for example.

Marketwatch reports its PE ratio without extraordinary items at 8.6, and the stock is trading right around book value. They have a US$6 billion share buyback and are on a path of increasing cash flow and dividends.

 

P/E w/o extraordinary          Book Value

Exxon            11.35                          1.54

BP                 12.1                            1.16

Chevron          14.42                          1.63

Shell               8.6                            0.98

 

Shell is well positioned for a growing LNG market, and it is continuing to high-grade its portfolio by divesting in lower margin assets. While most of the major integrated oil and gas companies are trading at highs on the chart, you can buy Shell at a good price after a bit of a correction.

It looks like the stock could break to the upside out of wedge pattern. There is resistance between US$54 and US$56, so we need a clear break above US$56 to confirm a new bullish move.

Support is between US$48 and US$50.

We can buy the stock now and get almost a 4% and growing dividend while we wait for capital appreciation.

Speculators could try the Call Options. I like the January 2023 $45 Call for around US$8.30.

It is US$7 in the money, so the premium is only US$1.30. A US$10 move in the stock would give you more than a double, but you won’t get the dividends with the options.

Struthers Stock Report Disclaimers: 

All forecasts and recommendations are based on opinion. Markets change direction with consensus beliefs, which may change at any time and without notice. The author/publisher of this publication has taken every precaution to provide the most accurate information possible. The information & data were obtained from sources believed to be reliable, but because the information & data source are beyond the author’s control, no representation or guarantee is made that it is complete or accurate.

The reader accepts information on the condition that errors or omissions shall not be made the basis for any claim, demand or cause for action. Because of the ever-changing nature of information & statistics the author/publisher strongly encourages the reader to communicate directly with the company and/or with their personal investment adviser to obtain up to date information.

Past results are not necessarily indicative of future results. Any statements non-factual in nature constitute only current opinions, which are subject to change. The author/publisher may or may not have a position in the securities and/or options relating thereto, & may make purchases and/or sales of these securities relating thereto from time to time in the open market or otherwise. Neither the information, nor opinions expressed, shall be construed as a solicitation to buy or sell any stock, futures or options contract mentioned herein. The author/publisher of this letter is not a qualified financial adviser & is not acting as such in this publication.

Disclosures: 

Charts provided by the author.

1) Ron Struthers: I, or members of my immediate household or family, own shares of the following companies mentioned in this article: None. I personally am, or members of my immediate household or family are, paid by the following companies mentioned in this article: None. My company currently has a financial relationship with the following companies mentioned in this article: None. I determined which companies would be included in this article based on my research and understanding of the sector.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.

4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services, or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees, or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in the securities mentioned. Directors, officers, employees, or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Opportunity for Investors Found in Psychedelics Space

Source: Patrick R. Trucchio  (9/27/22)

Treatment of alcohol use disorder with psychedelics plus therapy is effective, according to existing data, and the potential global market is large, noted an H.C. Wainwright & Co. report.

Awakn Life Sciences Corp. (AWKN:NEO; AWKNF:OTCQB) and Cybin Inc. (CYBN:NYSE American; CYBN:NEO) are best positioned to capitalize on the “robust potential of psychedelics in alcohol use disorder (AUD),” an estimated $20 billion-plus global market, purported H.C. Wainwright & Co. analyst Patrick Trucchio in a September 22, 2022 research note.

“With a potential addressable patient population in Western markets that exceeds 30 million people and with 10% or less of these patients in active treatment, the unmet medical need and opportunity for innovative approaches to treatment is very high,” Trucchio wrote. “As such, we believe the potential for psychedelics with therapy to ameliorate AUD could represent a significant opportunity for drug sponsors, which is highly underappreciated by investors.”

Two Leaders in the Space To Consider

Trucchio discussed Canada-based Awakn and Cybin, the two publicly traded biopharma companies that have announced AUD as a target indication. He noted both companies are worth an estimated $10 per share, “implying robust upside from current levels.”

One of them, Awakn, is pursuing ketamine, an NMDA receptor antagonist, plus psychotherapy in a variety of addiction disorders as well as MDMA plus therapy for AUD.

Over 32 weeks of observation, AUD patients treated with psilocybin plus therapy experienced “robust decreases in [their] percentage of heavy drinking days over and above those produced by active placebo and psychotherapy.”

 

The company’s lead clinical program, Project Kestrel, is supported by the Phase 2 trial in which KARE, or ketamine in the reduction of alcoholic relapse, and psychotherapy were administered to 96 patients with severe AUD. In this trial, patients achieved, on average, 86% abstinence at six months post-treatment compared to 2% pre-trial and 25% with the current standard of care.

Next for the program is a Phase 3 trial in the United Kingdom (U.K.), 66% of the costs of which the U.K.’s National Institute for Health and Care agreed to cover. Up to 280 AUD patients will be enrolled, treated, and followed for six to 12 months.

“The study is expected to be the largest ketamine-assisted therapy clinical trial and the only psychedelic Phase 3 trial receiving government funding,” Trucchio noted.

The clinical data supporting the use of psychedelics-assisted therapy in treating AUD and the size of the global AUD market bode well for Awakn and Cybin, which are pursuing the opportunity, and for investors in these companies that currently offer upside.

Awakn is also pursuing the use of MDMA plus therapy in AUD. The biopharma will explore a data licensing agreement with the U.S.-based Multidisciplinary Association for Psychedelic Studies, or MAPS, to support Awakn’s Phase 2b and planned Phase 3 studies evaluating MDMA-assisted therapy for AUD in Europe.

The second company in the space Trucchio highlighted, Cybin, is currently evaluating deuterated psilocybin, CYB003, as a treatment for major depressive disorder. The biopharma is expected to expand this program into AUD if the Phase 1/2a study, now underway, shows the compound to be safe, well-tolerated, and efficacious. Phase 1 data are due out by year-end, Phase 2a data by mid-2023.

Data Support Use of Psychedelics in Treating AUD

Trucchio pointed out the results of three robustly conducted trials that individually evaluated ketamine (Awakn’s Project Kestrel), MDMA (Imperial College London’s Bristol Imperial MDMA in Alcoholism, or BIMA, study), and psilocybin (study by Bogenschutz, Ross, Bhatt, et al.) showed a benefit in AUD patients.

“What is consistent in the data is that when administered in the proper set and setting with psychotherapy, psychoactive substances appear to ameliorate the cravings associated with AUD and thus, provide the potential for a significant reduction in heavy drinking days and even abstinence, both of which are approvable regulatory endpoints in the U.S. and Europe,” Trucchio wrote.

Results of the Bogenschutz et al. study were just published in JAMA’s Aug. 24, 2022 issue. The trial showed that over 32 weeks of observation, AUD patients treated with psilocybin plus therapy experienced “robust decreases in [their] percentage of heavy drinking days over and above those produced by active placebo and psychotherapy.”

The clinical data supporting the use of psychedelics-assisted therapy in treating AUD and the size of the global AUD market bode well for Awakn and Cybin, which are pursuing the opportunity, and for investors in these companies that currently offer upside.

 

Disclosures:
1) Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Awakn Life Sciences Corp. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with: Awakn Life Sciences Corp. Please click here for more information.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal  disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Awakn Life Sciences Corp., a company mentioned in this article.

6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures For H.C.Wainwright & Co., Awakn Life Sciences Corp a.nd Cybin Inc.,  September 22, 2022

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer.

I, Patrick R. Trucchio, CFA , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. Important disclosures and charts can be found on our disclaimer website: https://hcwco.bluematrix.com/sellside/ Disclosures.action

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously.

No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request.

H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report.

H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice.

Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

How many Amazon packages get delivered each year?

By Anne Goodchild, University of Washington and Rishi Verma, University of Washington

Curious Kids is a series for children of all ages. If you have a question you’d like an expert to answer, send it to [email protected].


How many Amazon packages get delivered each year? – Aya K., age 9, Illinois


It’s incredibly convenient to buy something online, right from your computer or phone. Whether it’s a high-end telescope or a resupply of toothpaste, the goods appear right at your doorstep. This kind of shopping is called “e-commerce” and it’s becoming more popular each year. In the U.S., it has grown from a mere 7% of retail purchases in 2012 to 19.6% of retail and US$791.7 billion in sales in 2020.

Amazon’s growing reach

For Amazon, the biggest player in e-commerce, this means delivering lots of packages. In 2021 the company shipped an estimated 7.7 billion packages globally, based on its nearly $470 billion in sales.

If each of these packages were a 1-foot square box and they were stacked on top of one another, the pile would be six times higher than the distance from the Earth to the Moon. Laid end to end, they would wrap around the Earth 62 times.

Back in the early 2010s, most things bought from Amazon.com were shipped using a third-party carrier like FedEx or UPS. In 2014, however, Amazon began delivering packages itself with a service called “Fulfilled by Amazon.” That’s when those signature blue delivery vans started appearing on local streets.

Since then, Amazon’s logistics arm has grown from relying entirely on other carriers to shipping 22% of all packages in the U.S. in 2021. This is greater than FedEx’s 19% market share and within striking distance of UPS’s 24%. Amazon’s multichannel fulfillment service allows other websites to use its warehousing and shipping services. So your order from Etsy or eBay could also be packed and shipped by Amazon.

Amazon came to dominate online shopping by offering free two-day shipping to Amazon Prime members.

The supply chain

To handle that many packages, shipping companies need an extensive network of manufacturers, vehicles and warehouses that can coordinate together. This is called the supply chain. If you’ve ever used a tracking number to follow a package, you’ve seen it in action.

People who make decisions about where to send vehicles and how to route packages are constantly trying to keep costs down while still getting packages to customers on time. The supply chain can do this very effectively, but it also has downsides.

More delivery vehicles on the road produce more greenhouse gas emissions that contribute to climate change, along with pollutants like nitrogen oxides and particulate matter that are hazardous to breathe. Traffic congestion is also a major concern in cities as delivery drivers try to find parking on busy streets.

Urban freight solutions

Are there ways to balance the increasing number of deliveries while making freight safe, sustainable and fast? At the University of Washington’s Supply Chain Transportation and Logistics Center, we work with companies like Amazon and UPS and others in the shipping, transportation and real estate sectors to answer questions like this. Here are some solutions for what we and our colleagues call the “last mile” – the last leg of a package’s long journey to your doorstep.

– Electrification: Transitioning from gasoline and diesel vehicles to fleets of electric or other zero-emission vehicles reduces pollution from delivery trucks. Tax credits and local policies, such as creating so-called green loading zones and zero-emission zones for clean vehicles, create incentives for companies to make the switch.

– Common carrier lockers: Buildings can install lockers at central locations, such as busy transit stops, so that drivers can drop off packages without going all the way to your doorstep. When you’re ready to pick up your items, you just stop by at a time that’s convenient for you. This reduces both delivery truck mileage and the risk of packages being stolen off of porches.

– Cargo bicycles: Companies can take the delivery truck out of the equation and use electric cargo bicycles to drop off smaller packages. In addition to being zero-emission, cargo bicycles are relatively inexpensive and easy to park, and they provide a healthier alternative for delivery workers.

To learn more about supply chains and delivery logistics, check with your town or city’s transportation department to see if they are testing or already have goods delivery programs or policies, like those in New York and Seattle. And the next time you order something for delivery, consider your options for receiving it, such as walking or biking to a package locker or pickup point, or consolidating your items into a single delivery.

Package delivery can be both convenient and sustainable if companies keep evolving their supply chains, and everyone thinks about how they want delivery to work in their neighborhoods.


Hello, curious kids! Do you have a question you’d like an expert to answer? Ask an adult to send your question to [email protected]. Please tell us your name, age and the city where you live.

And since curiosity has no age limit – adults, let us know what you’re wondering, too. We won’t be able to answer every question, but we will do our best.The Conversation

About the Author:

Anne Goodchild, Professor of Civil and Environmental Engineering and Director, Supply Chain Transportation and Logistics Center, University of Washington and Rishi Verma, PhD Student in Industrial Engineering and Research Assistant, Urban Freight Lab, University of Washington

This article is republished from The Conversation under a Creative Commons license. Read the original article.

 

Biopharma Co.’s Shares Roll to New 52-Week High Price

Source: Streetwise Reports  (10/12/22)

Shares of DICE Therapeutics Inc. traded 62% higher yesterday and established a new 52-week intraday high after the company reported positive topline data from its Phase 1 DC-806 Psoriasis study.

Biopharmaceutical company DICE Therapeutics Inc. (DICE:NASDAQ), which utilizes its proprietary technology platform to create and develop novel oral therapeutic candidates for use in the treatment of chronic immune and other diseases, yesterday announced “positive topline data from its Phase 1 clinical trial of DC-806, an oral small molecule antagonist of the pro-inflammatory cytokine IL-17.”

The company advised that DC-806 is its leading interleukin-17 (IL-17) antagonist that is being evaluated as a potential treatment for psoriasis. The firm noted that DC-806 has been well tolerated in the Phase 1 trial across all dose groups in healthy volunteers and psoriasis patients with a robust PK profile.

DICE Therapeutics indicated that both high and low doses of DC-806 administered to participants in the study provided clear beneficial pharmacodynamic results on two distinct biomarkers.

DICE shares opened 79% higher yesterday at $44.18 (+$14.265, +57.87%) over last Friday’s $24.65 closing price and reached a new 52-week high price yesterday morning of $45.99.

The company explained that the randomized, double-blind Phase 1 trial was designed to evaluate the safety and pharmacokinetics of DC-806 in healthy volunteers and to serve as the basis for the potential use treatment of psoriasis patients.

The study included overlapping modules that included a Phase 1a single ascending dose, Phase 1b multiple ascending doses, and Phase 1c, which was structured under a proof-of-concept context for use in treating patients with psoriasis.

The firm emphasized that in the clinical proof-of-concept portion of the trial (Phase 1c), “psoriasis patients achieved with a mean percentage reduction in PASI from baseline at four weeks of 43.7% in the high dose group compared to 13.3% in the placebo group.”

DICE Therapeutics advised that the data gathered in the trials provide staunch support for advancing DC-806 as a potential oral agent for treating psoriasis. The firm added that it intends to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) during H1/23 and stated that it plans to move forward with a dose-ranging Phase 2b clinical trial in patients with moderate-to-severe psoriasis in H1/23.

DICE Therapeutics’ CEO Kevin Judice, Ph.D. stated, “We are extremely excited by the overall clinical profile of DC-806 and clear proof-of-concept in psoriasis in this Phase 1 clinical trial, which we believe is the first-ever clinical demonstration of direct inhibition of a cytokine with a small molecule.”

Judice continued, “We believe these data not only support further development of DC-806 as a potential best-in-class oral therapy for psoriasis, but also may unlock additional IL-17-mediated disease indications given DC-806’s excellent safety profile, strong PK data, and robust dose-dependent target engagement.”

The company’s Chief Medical Officer, Tim Lu, M.D., Ph.D., remarked, “Based on the Phase 1 clinical trial, we believe DC-806 has the potential to be the best-in-class oral therapeutic agent for patients with psoriasis…Data from this Phase 1 clinical trial provides early evidence for the potential differentiation of DC-806 on efficacy, safety, and ease of use. We look forward to advancing DC-806 into a Phase 2b clinical trial to optimize dosing and further explore peak efficacy with a longer duration of treatment.”

DICE listed that “it is developing orally-available, small molecule antagonists of the pro-inflammatory signaling molecule IL-17, an immune cell-derived cytokine that is produced in response to infection by certain microorganisms.”

The company stated in the report that there is no cure for psoriasis, which “manifests as erythematous plaques with thick scaling that can occur anywhere on the body.” The disease causes symptoms that typically include itchiness, pain, and bleeding from scratching, which often results in scarring and disfiguration. The firm stated that according to the National Psoriasis Association, psoriasis affects about 125 million people globally.

DICE Therapeutics is a clinical-stage biopharma company based in South San Francisco, Calif., that focuses on developing and advancing new medicines for treating chronic autoimmune and inflammatory diseases.

The firm uses its proprietary DELSCAPE platform to build a pipeline of novel oral therapeutics to address well-validated targets in immunology that match or exceed the potency of their systemic biologic counterparts. The DELSCAPE platform can identify and discover selective oral small molecules that demonstrate potential for modulating protein-protein interactions (PPIs) that are equal to or better than systemic biologics.

DICE Therapeutics started off yesterday with a market cap of around $941.9 million, with approximately 38.21 million shares outstanding and a short interest of about 12.9%. DICE shares opened 79% higher yesterday at $44.18 (+$14.265, +57.87%) over last Friday’s $24.65 closing price and reached a new 52-week high price yesterday morning of $45.99. The stock traded between $36.56 and $45.99 per share and closed for trading at $40.00 (+$15.35, +62.27%).

Disclosures:
1) Stephen Hytha wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Netflix (NFLX) Stock rose sharply today, Trend remains lower but flattening

By InvestMacro.com | #stocks #NFLX #Netflix

Netflix, Inc. End of Day Update: October 13 2022

The Netflix, Inc. (NFLX) stock jumped today with a strong increase of 9.32 percent and closed the day around the 232.51 price level, according to unofficial data at the New York close.

Netflix, a leading technology streaming company, opened the trading day at 212.69 price level with the high of the day at 234.47 and the low of the day at 211.73.

There was news out today for Netflix as the company announced a new ad-supported membership plan that will cost $6.99 in the US and international markets.

The NFLX Trend is Down, RSI level is Bullish

The stock is currently trending lower over the past 200 trading days, according to the linear regression line (red) seen on the chart below. Despite the downtrend this year, the Netflix stock has started to see a moderate uptick from its lows of earlier in the year and the 20-day moving average has been flat in the past few months.

The Relative Strength Index, an indicator that can identify overbought (above 70) and oversold levels (below 30), shows that the current RSI is at a 50.7 score. This is a Bullish reading on the daily time-frame of the standard RSI Indicator. The chart below uses a smoothed (moving average of levels) version of the RSI that will lag slightly but be more consistent.

Netflix (NFLX) Stock rose sharply today, Trend remains lower but flattening

NFLX Price Returns (Closing Price Changes)

The NFLX has declined by -3.00 percent over the past 10 days while seeing a move higher by 4.00 over the past 30 days. The 90-day change is 17.94 while the 180-day return and the 365-day return are -35.36 and -53.79, respectively.

By InvestMacro.com – – Get our stock market newsletter for stock rankings, charts & updates

Apple (AAPL) Stock today rose higher after 3-month low, Trend remains down

By InvestMacro.com | #stocks #AAPL #Apple

Apple Inc. End of Day Update: October 13 2022

The Apple Inc. (AAPL) stock finished the day with a rise of 2.77 percent and closed the day at the 142.99 price level, according to unofficial data at the New York close.

Apple, an American technology company famous for its devices, opened the trading day at 139.13 price level with the high of the day at 143.59 and the low of the day dropping to 134.37.

The Apple stock had been dropping the majority of days over the past week and today fell to its lowest level in over three months below the $135 threshold. Apple found support at the major levels of $135 and $140 today to help boost the stock higher.

The AAPL Trend is Lower, RSI level is Bearish

The stock is currently trending down over the past 200 trading days, according to the linear regression line (red) seen on the chart below. AAPL trades under its 20-day moving average as well with the linear regression line and 20-day moving average line now converging near the $146 price area.

The Relative Strength Index, an indicator that can identify overbought (above 70) and oversold levels (below 30), shows that the current RSI is at a 42.4 score. This is a Bearish reading on the daily time-frame.

Apple (AAPL) Stock today rose higher after 3-month low, Trend remains down

AAPL Price Returns (Closing Price Changes)

The AAPL has seen an increase by 0.36 percent over the past 10 days while seeing a decline of -9.05 over the past 30 days. The 90-day change is -2.02 while the 180-day return and the 365-day return are -10.09 and 12.84, respectively.

By InvestMacro.com – – Get our stock market newsletter for stock rankings, charts & updates

NVIDIA (NVDA) Stock gains by 9%. Trend is Down, RSI Bearish

By InvestMacro.com | #stocks #NVDA #NVIDIA

NVIDIA Corporation End of Day Update: October 13 2022

The NVIDIA Corporation (NVDA) stock finished the day with an advance of 9.01 percent and closed the day around the 119.60 price level, according to unofficial data at the New York close.

NVIDIA, a technology company that is recognized as a leader in GPU units for computers, opened the trading day at 109.71 price level with the high of the day at 120.78 and the low of the day falling to 108.13.

NVIDIA’s stock had fallen in four out of the previous five days and has dipped to trading at its lowest levels in two years, dating back to August 2020.

The NVDA Trend is Lower, RSI level is Bearish

The stock is currently trending sharply lower over the past 200 trading days, according to the linear regression line (red) seen on the chart below. NVDA has lost approximately over half of its share price value since December 2021.

The Relative Strength Index, an indicator that can identify overbought (above 70) and oversold levels (below 30), shows that the current RSI is at a 38.5 score. This is a Bearish reading on the daily time-frame.

NVIDIA (NVDA) Stock gains by 9%. Trend is Down, RSI Bearish

NVDA Price Returns (Closing Price Changes)

The NVDA is lower by -2.13 percent over the past 10 days while seeing a step lower by -20.76 over the past 30 days. The 90-day change is -36.32 while the 180-day return and the 365-day return are -47.46 and -16.59, respectively.

By InvestMacro.com – – Get our stock market newsletter for stock rankings, charts & updates

Intel (INTC) Stock jumped today, Trend remains down

By InvestMacro.com | #stocks #INTC #RSIDivergence

Intel Corporation End of Day Update: October 13 2022

The Intel Corporation (INTC) stock finished the day with an advance of 6.86 percent and closed the day around the 26.42 price level, according to unofficial data at the New York close.

Intel, an American technology and chip company, opened the trading day at 24.725 price level with the high of the day being 26.84 and the low of the day bottoming at 24.59.

The stock today hit its lowest level for share prices since August of 2015 before turning around and surging higher to close out the day ahead.

The INTC Trend is Down, RSI level is Bearish

The stock is currently trending sharply lower over the past 200 trading days, according to the linear regression line (red) seen on the chart below. Intel has lost approximately half of its share price value from December 2021 when it was trading in the $50s compared to the current state of the price.

The Relative Strength Index, an indicator that can identify overbought (above 70) and oversold levels (below 30), shows that the current RSI is at a 39.4 score. This is a Bearish reading on the daily time-frame currently. The RSI had recently been in oversold territory and has emerged with an RSI divergence at the current moment (price lower while RSI score higher).

Intel (INTC) Stock jumped today, Trend remains down

INTC Price Returns (Closing Price Changes)

INTC has seen an increase by 0.15 percent over the past 10 days while seeing a decline by -17.23 over the past 30 days. The 90-day change is -38.42 while the 180-day return and the 365-day return are -47.57 and -51.43, respectively.

By InvestMacro.com – – Get our stock market newsletter for stock rankings, charts & updates

NIO Stock up by over 3%, breaks 6-day losing streak. RSI is Oversold

By InvestMacro.com | #stocks #NIO #RSI-Oversold

NIO Inc. End of Day Update: October 13 2022

The NIO Inc. (NIO) stock finished the day with a gain of 3.48 percent and closed the day around the 12.78 price level, according to unofficial data at the New York close.

NIO opened the trading day at the 12.35 price level with the high of the day being 12.85 and the low of the day at 11.95.

The stock bounced off of the $12.00 support level today after touching the lowest trading level since May. NIO had dropped for six straight days and for fourteen out of the previous eighteen days before today’s rebound.

The NIO Trend is Lower, RSI level is Bearish-Oversold

The stock is currently trending lower over the past 200 trading days, according to the linear regression best-fit line (red) seen on the chart below. NIO shares had been trading as high as $40 dollars in December of 2021 before trending lower over the course of this year.

The Relative Strength Index, an indicator that can identify overbought (above 70) and oversold levels (below 30), shows that the current RSI is at a 27.2 score. This is a Bearish-Oversold reading on the daily time-frame.

NIO Stock up by over 3%, breaks 6-day losing streak. RSI is Oversold

NIO Price Returns (Closing Price Changes)

The NIO has slid by -17.97 percent over the past 10 days while seeing a decline of -35.81 over the past 30 days. The 90-day change is -33.37 while the 180-day return and the 365-day return are -43.60 and -66.31, respectively.

By InvestMacro.com – – Get our stock market newsletter for stock rankings, charts & updates

Biopharma Co. Partners With Merck for Combo Drug Trial

Source: Dr. Joseph Pantginis  (10/12/22)

With this and other clinical studies, the U.S. company has a busy and, thus, catalyst-rich Q4/22 ahead, noted an H.C. Wainwright & Co. report.

Compass Therapeutics Inc. (CMPX:NASDAQ) entered a partnership with Merck & Co. Inc. (MRK:NYSE) to conduct a clinical trial evaluating the combination treatment of Compass’ CTX-471 plus Merck’s Keytruda in a subpopulation of patients with certain metastatic or locally advanced cancers, reported H.C. Wainwright & Co. analyst Dr. Joseph Pantginis in an October 11, 2022 research note. CTX-471 is a monoclonal antibody targeting CD137.

“Phase 1b is an important signal-seeking study,” Pantginis wrote.

Also of note, the Massachusetts-based biopharma offers investors significant potential return, as indicated by its current share price of US$3.11 and H.C. Wainwright’s target price on the company of US$12 per share.

Participants in the Phase 1b collaboration study will be patients with non-small cell lung cancer, small cell lung cancer, melanoma, or squamous cell carcinoma of the head and neck who progressed after receiving checkpoint inhibitor therapy. In the trial, after a patient progresses, they will be given CTX-471 plus Keytruda. Part one of the study will test escalating doses of CTX-471 and a fixed Keytruda dose. Part two will test expanding doses.

Also of note, the Massachusetts-based biopharma offers investors significant potential return, as indicated by its current share price of US$3.11 and H.C. Wainwright’s target price on the company of US$12 per share.

Pantginis pointed out that Merck and other big pharmaceutical firms are now highly selective when collaborating regarding their checkpoint inhibitors. Merck having agreed to join forces with Compass, suggests “the combination approach must make mechanistic sense, and we believe combining CTX-471 and Keytruda fits the bill.”

Other Plans for Pipeline

In addition to this Phase 1b, Compass intends to conduct two additional CTX-471 studies. One is a post-cyclin-dependent kinase inhibitor salvage study, Pantginis relayed. The other will test induction therapy of carboplatin/etoposide/atezolizumab followed by maintenance atezolizumab plus/minus CTX-471 as a first-line treatment for small cell lung cancer patients.

Near-Term Catalysts

Compass is busy this quarter with several “meaningful milestones lined up, noted Pantginis. The “leading value driver” for the biopharma, according to Pantginis, is the start of a Phase 2/3 study in the U.S. of CTX-009 in biliary tract cancer.

Other potential stock-moving events are the start of a Phase 2 study of CTX-009 in advanced colorectal cancer and the completion of Phase 1b CTX-471 monotherapy study in various cancers. Finally, Compass is targeting Q4/22 for submitting an investigational new drug application for CTX-8371.

H.C. Wainwright has a Buy rating on Compass.

“Our focus is squarely on Compass’ clinical data delivered by CTX-009, to date, as well as its strong cash balance to weather these depressing markets,” Pantginis wrote.

Disclosures:
1) Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with: None. Please click here for more information.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal  disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures For H.C.Wainwright & Co., Compass Therapeutics Inc., October 11, 2022

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer.

I, Joseph Pantginis, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst’s household has a financial interest in the securities of Compass Therapeutics, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of September 30, 2022 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Compass Therapeutics, Inc..

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The firm or its affiliates received compensation from Compass Therapeutics, Inc. for non-investment banking services in the previous 12 months. The Firm or its affiliates did receive compensation from Compass Therapeutics, Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Compass Therapeutics, Inc. during the past 12 months. The Firm does not make a market in Compass Therapeutics, Inc. as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously.

No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal – investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report.

H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice.

Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

 

 

Pantginis pointed out that Merck and other big pharmaceutical firms are now highly selective when collaborating regarding their checkpoint inhibitors. Merck having agreed to join forces with Compass, suggests “the combination approach must make mechanistic sense, and we believe combining CTX-471 and Keytruda fits the bill.”